1423018-12-5

1423018-12-5 structure

Name: LY2922470
Chemical Name: (3S)-3-[4-({5-[(8-Methoxy-3,4-dihydro-1(2H)-quinolinyl)methyl]-2-thienyl}methoxy)phenyl]-4-hexynoic acid
CAS Number: 1423018-12-5
Molecular Formula: C₂₈H₂₉NO₄S
Molecular Weight: 475.599
Catalog: Signaling Pathways GPCR/G Protein GPR40
Create Date: 2018-06-02 17:12:32
Modify Date: 2025-08-27 11:38:53
LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40), with EC50s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with significant increases in insulin and GLP-1, is potential for the treatment of type 2 diabetes mellitus (T2DM)[1].

Name	(3S)-3-[4-({5-[(8-Methoxy-3,4-dihydro-1(2H)-quinolinyl)methyl]-2-thienyl}methoxy)phenyl]-4-hexynoic acid
Synonyms	MFCD30489363 (3S)-3-[4-({5-[(8-Methoxy-3,4-dihydro-1(2H)-quinolinyl)methyl]-2-thienyl}methoxy)phenyl]-4-hexynoic acid Benzenepropanoic acid, 4-[[5-[(3,4-dihydro-8-methoxy-1(2H)-quinolinyl)methyl]-2-thienyl]methoxy]-β-1-propyn-1-yl-, (βS)-

Description	LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40), with EC50s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with significant increases in insulin and GLP-1, is potential for the treatment of type 2 diabetes mellitus (T2DM)[1].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> GPR40 Research Areas >> Metabolic Disease
Target	EC50：7 nM (human GPR40), 1 nM (mouse GPR40), 3 nM (rat GPR40)[1]
References	[1]. Hamdouchi C, et al. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). J Med Chem. 2016 Dec 22;59(24):10891-10916.